Natpar (Parathyroid Hormone)

Parathyroid hormone, the active ingredient in Natpar, is a Parathyroid hormone analog presented as an injectable solution for subcutaneous use. It treats hypoparathyroidism by increasing serum calcium levels in patients with deficient endogenous hormone.

GNH USA supplies Natpar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide, ensuring quality‑controlled distribution and regulatory compliance across multiple markets. The company adheres to stringent Good Distribution Practice standards, provides cold‑chain logistics for biologic products, and supports customers with technical and regulatory assistance throughout the supply chain.

Natpar is a parathyroid hormone analog used to manage disorders of calcium metabolism, particularly hypoparathyroidism. - Chronic hypoparathyroidism: restores and maintains normal serum calcium concentrations in patients with long‑term deficiency of endogenous parathyroid hormone. - Post‑surgical hypoparathyroidism: corrects acute hypocalcemia following thyroid or parathyroid surgery when natural hormone production is insufficient. - Severe hypocalcemia unresponsive to conventional therapy: provides an alternative means to raise calcium levels when oral calcium and vitamin D supplementation fail.

Parathyroid hormone therapy may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Nausea: mild gastrointestinal discomfort occurring shortly after injection. - Injection site reactions: redness, swelling or pain at the subcutaneous administration site. - Headache: transient cranial discomfort reported by some patients. - Hypercalcemia (mild): slight elevation of serum calcium that is usually manageable with dose adjustment.

Serious or Rare Side Effects: - Severe hypercalcemia: marked increase in calcium that can cause cardiac arrhythmias or renal impairment. - Ectopic calcification: deposition of calcium in soft tissues, potentially affecting kidneys or vasculature. - Anaphylactic reaction: rare systemic hypersensitivity requiring immediate medical intervention. - Osteosarcoma (theoretical risk): observed in animal studies, considered a potential but unproven risk in humans.

When using Natpar, clinicians should observe specific safety measures to minimize risks and ensure therapeutic effectiveness. - Monitor serum calcium: check calcium levels regularly and adjust dose to maintain target range. - Adjust dose in renal impairment: reduce dosage or increase monitoring in patients with reduced kidney function. - Caution in hypercalcemia: avoid use or lower dose if baseline calcium is elevated. - Pregnancy and lactation: safety has not been established; use only if potential benefit justifies risk. - Concomitant calcium or vitamin D therapy: evaluate need to prevent excessive calcium rise. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Parathyroid hormone can interact with other agents that influence calcium balance or bone metabolism.

Major Interactions (Avoid): - High‑dose calcium supplements: may cause dangerous hypercalcemia when combined with Natpar. - High‑dose vitamin D analogs (calcitriol, alfacalcidol): synergistic increase in calcium absorption. - Thiazide diuretics: reduce renal calcium excretion, raising risk of hypercalcemia.

Moderate Interactions (Monitor Closely): - Bisphosphonates: may blunt the bone‑resorbing effect of Natpar, affecting calcium response. - Calcitonin therapy: opposing actions on calcium homeostasis may require dose adjustments. - Loop diuretics: increase calcium excretion, potentially necessitating higher Natpar dose.